Merck Reports Q3 Sales of $18.1B, Outlook Raised to $66.8B-$67.3B
Merck & Co. announced Q3 2026 sales of $18.1B with oncology product Keytruda leading growth. The company raised its full-year sales guidance to $66.8B-$67.3B.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed